Lakeside Signs $1.5 Million Sales Agreement with Sinopharm Group Subsidiary

Agreement to Deliver Critical Medicines 

ITASCA, Ill., Dec. 17, 2024 /PRNewswire/ -- Lakeside Holding Limited ("Lakeside" or the "Company") (Nasdaq: LSH), a U.S.-based cross-border supply chain solution provider with a unique focus on the Asia-Pacific market is pleased to announce that Hupan Pharmaceutical has signed a Sales Agreement (the "Agreement") with Sinopharm Holding Hubei New Special Medicine Co., Ltd. ("Sinopharm Hubei"), a subsidiary of Sinopharm Group. The Agreement, valued at approximately RMB 11.0 million (approximately $1.5 million), is effective from January 1, 2025, through the end of the year and involves the sale and delivery of critical medicines, including Sodium Bicarbonate, Glucose, and Glucose Sodium Chloride.